Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $1.3 million.

  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) rose 5.97% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 1.82%. This contributed to the annual value of $4.7 million for FY2024, which is 10.68% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $1.3 million for Q3 2025, which was up 8.15% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q3 2025 and a low of $370,000 during Q2 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.1 million (2023), whereas its average is $1.1 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 160.00% in 2022, then declined by 10.40% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Depreciation & Amortization (CF) stood at $390,000 in 2021, then spiked by 160.00% to $1.0 million in 2022, then increased by 8.68% to $1.1 million in 2023, then decreased by 0.54% to $1.1 million in 2024, then increased by 5.97% to $1.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.3 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.1 million in Q1 2025.